<html><head></head><body><h1>Hyoscyamine, Atropine, Scopolamine, and Phenobarbital</h1><ul class="ddc-anchor-links"><li>Pharmacology</li>
<li>Uses</li>
<li>Contraindications</li>
<li>Dosage</li>
<li>Storage</li>
<li>Interactions</li>
<li>Warnings</li>
<li>Pregnancy</li>
<li>Patient education</li></ul><h2>Pronunciation</h2><p>(hye oh SYE a meen, A troe peen, skoe POL a meen, &amp; fee noe BAR bi tal)</p><h2>Index Terms</h2><ul><li>Atropine, Hyoscyamine, Phenobarbital, and Scopolamine</li><li>Belladonna Alk/Phenobarbital</li><li>Belladonna Alkaloids With Phenobarbital</li><li>Phenobarbital, Hyoscyamine, Atropine, and Scopolamine</li><li>Scopolamine, Hyoscyamine, Atropine, and Phenobarbital</li></ul><h2>Dosage Forms</h2><p>Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product.</p><p>Elixir, Oral:</p><p>Donnatal: Hyoscyamine sulfate 0.1037 mg, atropine sulfate 0.0194 mg, scopolamine hydrobromide 0.0065 mg, and phenobarbital 16.2 mg per 5 mL (120 mL, 480 mL) [contains ethanol &lt;23.8%; grape flavor]</p><p>Donnatal: Hyoscyamine sulfate 0.1037 mg, atropine sulfate 0.0194 mg, scopolamine hydrobromide 0.0065 mg, and phenobarbital 16.2 mg per 5 mL (120 mL, 480 mL) [contains ethanol &lt;23.8%, tartrazine; mint flavor]</p><p>Generic: Hyoscyamine sulfate 0.1037 mg, atropine sulfate 0.0194 mg, scopolamine hydrobromide 0.0065 mg, and phenobarbital 16.2 mg per 5 mL (120 mL, 480 mL)</p><p>Tablet, Oral:</p><p>Donnatal: Hyoscyamine sulfate 0.1037 mg, atropine sulfate 0.0194 mg, scopolamine hydrobromide 0.0065 mg, and phenobarbital 16.2 mg</p><p>Phenohytro: Hyoscyamine sulfate 0.1037 mg, atropine sulfate 0.0194 mg, scopolamine hydrobromide 0.0065 mg, and phenobarbital 16.2 mg</p><p>Generic: Hyoscyamine sulfate 0.1037 mg, atropine sulfate 0.0194 mg, scopolamine hydrobromide 0.0065 mg, and phenobarbital 16.2 mg</p><h2>Brand Names: U.S.</h2><ul><li>Donnatal</li><li>Phenohytro</li></ul><h2>Pharmacologic Category</h2><ul><li>Anticholinergic Agent</li><li>Antispasmodic Agent, Gastrointestinal</li></ul><h2 class="ddc-anchor-offset" id="pharmacology">Pharmacology</h2><p>Anticholinergic agents (hyoscyamine, atropine, and scopolamine) inhibit the muscarinic actions of acetylcholine at the postganglionic parasympathetic neuroeffector sites including smooth muscle, secretory glands, and CNS sites; specific anticholinergic responses are dose-related.</p><h3>Absorption</h3><p>Well absorbed from the GI tract</p><h2 class="ddc-anchor-offset" id="uses">Use: Labeled Indications</h2><p>Adjunct in treatment of irritable bowel syndrome, acute enterocolitis, duodenal ulcer</p><h2 class="ddc-anchor-offset" id="contraindications">Contraindications</h2><p>Hypersensitivity to hyoscyamine, atropine, scopolamine, phenobarbital, or any component of the formulation; narrow-angle glaucoma; GI and GU obstruction; myasthenia gravis; paralytic ileus; intestinal atony; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis (especially complicated by toxic megacolon); hiatal hernia associated with reflux esophagitis; acute intermittent porphyria; restlessness and/or excitement caused by phenobarbital </p><h2 class="ddc-anchor-offset" id="dosage">Dosing: Adult</h2><p><b>Duodenal ulcer, irritable bowel syndrome, and acute enterocolitis, adjunct treatment:</b> Oral: 1 to 2 tablets <b>or</b> 5 to 10 mL of elixir 3 to 4 times/day</p><h2>Dosing: Geriatric</h2><p>Avoid use (Beers Criteria [AGS 2019]).</p><h2>Dosing: Pediatric</h2><p><b>Duodenal ulcer, irritable bowel syndrome, and acute enterocolitis, adjunct treatment:</b></p><p>Infants weighing ≥4.5 kg, Children, and Adolescents: Immediate release (Donnatal elixir):</p><p>4.5 to &lt;9.1 kg: 0.5 mL every 4 hours <b>or</b> 0.75 mL every 6 hours</p><p>9.1 to &lt;13.6 kg: 1 mL every 4 hours <b>or</b> 1.5 mL every 6 hours</p><p>13.6 to &lt;22.7 kg: 1.5 mL every 4 hours <b>or</b> 2 mL every 6 hours</p><p>22.7 to &lt;34 kg: 2.5 mL every 4 hours <b>or</b> 3.75 mL every 6 hours</p><p>34 to &lt;45.4 kg: 3.75 mL every 4 hours <b>or</b> 5 mL every 6 hours</p><p>≥45.4 kg: 5 mL every 4 hours <b>or</b> 7.5 mL every 6 hours</p><h2 class="ddc-anchor-offset" id="storage">Storage</h2><p>Store at controlled room temperature 20°C to 25°C (68°F to 77°F). Protect from light and moisture. Avoid freezing (elixir). </p><h2 class="ddc-anchor-offset" id="interactions">Drug Interactions</h2><p>Abemaciclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Abemaciclib. <i> Avoid combination</i></p><p>Abiraterone Acetate: CYP3A4 Inducers (Strong) may decrease the serum concentration of Abiraterone Acetate.  Management: Avoid whenever possible. If such a combination cannot be avoided, increase abiraterone acetate dosing frequency from once daily to twice daily during concomitant use.<i> Consider therapy modification</i></p><p>Acalabrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Acalabrutinib.  Management: Avoid co-administration of strong CYP3A inducers in patients taking acalabrutinib. If strong CYP3A inducers cannot be avoided, increase the dose of acalabrutinib to 200 mg twice daily.<i> Consider therapy modification</i></p><p>Acetaminophen: Barbiturates may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage. <i> Monitor therapy</i></p><p>Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Monitor therapy</i></p><p>Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>Afatinib: PHENobarbital may decrease the serum concentration of Afatinib.  Management: Consider increasing the afatinib dose by 10 mg as tolerated in patients requiring chronic coadministration of phenobarbital with afatinib. Reduce afatinib dose back to the original afatinib dose 2 to 3 days after discontinuation of phenobarbital.<i> Consider therapy modification</i></p><p>Albendazole: PHENobarbital may decrease serum concentrations of the active metabolite(s) of Albendazole. <i> Monitor therapy</i></p><p>Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Monitor therapy</i></p><p>Alfentanil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Alfentanil.  Management: If concomitant use of alfentanil and strong CYP3A4 inducers is necessary, consider dosage increase of alfentanil until stable drug effects are achieved. Monitor patients for signs of opioid withdrawal.<i> Consider therapy modification</i></p><p>Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Alpelisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Alpelisib. <i> Avoid combination</i></p><p>Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Monitor therapy</i></p><p>Amezinium: Atropine (Systemic) may enhance the stimulatory effect of Amezinium. <i> Monitor therapy</i></p><p>Amphetamines: May decrease the serum concentration of PHENobarbital.<i> Monitor therapy</i></p><p>Antacids: May decrease the serum concentration of Hyoscyamine. Management: Administer immediate release hyoscyamine before meals and antacids after meals when these agents are given in combination.<i> Consider therapy modification</i></p><p>Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Monitor therapy</i></p><p>Antihepaciviral Combination Products: CYP3A4 Inducers (Strong) may decrease the serum concentration of Antihepaciviral Combination Products. <i> Avoid combination</i></p><p>Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.  Management: Avoid concurrent use of apixaban with strong CYP3A4 inducers whenever possible. Use of a strong CYP3A4 inducer with apixaban should be strictly avoided in any patient who is using an agent (either the CYP3A4 inducer or a third drug) that induces P-gp.<i> Consider therapy modification</i></p><p>Apremilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apremilast. <i> Avoid combination</i></p><p>Aprepitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Aprepitant. <i> Avoid combination</i></p><p>ARIPiprazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of ARIPiprazole.  Management: For indications other than major depressive disorder: double the oral aripiprazole dose over 1 to 2 weeks and closely monitor. Avoid use of strong CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.<i> Consider therapy modification</i></p><p>ARIPiprazole Lauroxil: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil.  Management: Patients taking the 441 mg dose of aripiprazole lauroxil increase their dose to 662 mg if used with a strong CYP3A4 inducer for more than 14 days. No dose adjustment is necessary for patients using the higher doses of aripiprazole lauroxil.<i> Consider therapy modification</i></p><p>Artemether: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Artemether. Specifically, dihydroartemisinin concentrations may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Artemether. <i> Avoid combination</i></p><p>Asunaprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Asunaprevir. <i> Avoid combination</i></p><p>Avanafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Avanafil. <i> Avoid combination</i></p><p>Avapritinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Avapritinib. <i> Avoid combination</i></p><p>Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib. <i> Avoid combination</i></p><p>Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Avoid combination</i></p><p>Barnidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Barnidipine. <i> Monitor therapy</i></p><p>Bazedoxifene: PHENobarbital may decrease the serum concentration of Bazedoxifene. This may lead to loss of efficacy or, if bazedoxifene is combined with estrogen therapy, an increased risk of endometrial hyperplasia. <i> Monitor therapy</i></p><p>Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline. <i> Avoid combination</i></p><p>Benperidol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Benperidol. <i> Monitor therapy</i></p><p>Benzhydrocodone: PHENobarbital may enhance the CNS depressant effect of Benzhydrocodone. PHENobarbital may decrease serum concentrations of the active metabolite(s) of Benzhydrocodone. Specifically, phenobarbital may decrease serum concentrations of hydrocodone.  Management: Avoid use of benzhydrocodone and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased benzhydrocodone efficacy and withdrawal if combined.<i> Consider therapy modification</i></p><p>Beta-Blockers: Barbiturates may decrease the serum concentration of Beta-Blockers. <i> Monitor therapy</i></p><p>Betamethasone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Betamethasone (Systemic). <i> Monitor therapy</i></p><p>Bictegravir: PHENobarbital may decrease the serum concentration of Bictegravir.  Management: When possible consider using an alternative anticonvulsant with concurrent bictegravir, emtricitabine, and tenofovir alafenamide. If the combination must be used, monitor closely for evidence of reduced antiviral effectiveness.<i> Consider therapy modification</i></p><p>Bisoprolol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bisoprolol. <i> Monitor therapy</i></p><p>Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Consider therapy modification</i></p><p>Blood Pressure Lowering Agents: Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Monitor therapy</i></p><p>Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib. <i> Avoid combination</i></p><p>Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib. <i> Avoid combination</i></p><p>Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Monitor therapy</i></p><p>Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased. <i> Monitor therapy</i></p><p>Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Monitor therapy</i></p><p>Brexpiprazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brexpiprazole.  Management: If brexpiprazole is used together with a strong CYP3A4 inducer, the brexpiprazole dose should gradually be doubled over the course of 1 to 2 weeks. Decrease brexpiprazole to original dose over 1 to 2 weeks if the strong CYP3A4 inducer is discontinued.<i> Consider therapy modification</i></p><p>Brigatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brigatinib. <i> Avoid combination</i></p><p>Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Bromocriptine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bromocriptine. <i> Monitor therapy</i></p><p>Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Avoid combination</i></p><p>Buprenorphine: PHENobarbital may enhance the CNS depressant effect of Buprenorphine. PHENobarbital may decrease the serum concentration of Buprenorphine.  Management: Avoid use of buprenorphine and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased buprenorphine efficacy and withdrawal if combined.<i> Consider therapy modification</i></p><p>BuPROPion: CYP2B6 Inducers (Weak) may decrease the serum concentration of BuPROPion. <i> Monitor therapy</i></p><p>BusPIRone: CYP3A4 Inducers (Strong) may decrease the serum concentration of BusPIRone.  Management: Consider alternatives to this combination. If coadministration of these agents is deemed necessary, monitor patients for reduced buspirone effects and increase buspirone doses as needed.<i> Consider therapy modification</i></p><p>Cabazitaxel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabazitaxel. <i> Monitor therapy</i></p><p>Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.  Management: Avoid use of strong CYP3A4 inducers with cabozantinib if possible. If combined, increase cabozantinib capsules (Cometriq) by 40 mg from previous dose, max 180 mg daily. Increase cabozantinib tablets (Cabometyx) by 20 mg from previous dose, max 80 mg daily<i> Consider therapy modification</i></p><p>Calcifediol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Calcifediol. <i> Monitor therapy</i></p><p>Calcium Channel Blockers: Barbiturates may increase the metabolism of Calcium Channel Blockers.  Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.<i> Monitor therapy</i></p><p>Canagliflozin: PHENobarbital may decrease the serum concentration of Canagliflozin.  Management: Consider increasing canagliflozin dose to 200 mg/day in patients tolerating 100 mg/day. A further increase to 300 mg/day can be considered in patients with an estimated glomerular filtration rate (GFR) of 60 mL/min/1.73 m2 or greater.<i> Consider therapy modification</i></p><p>Cannabidiol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cannabidiol. <i> Monitor therapy</i></p><p>Cannabidiol: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Cannabis: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be decreased. <i> Monitor therapy</i></p><p>Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Capmatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Capmatinib. <i> Avoid combination</i></p><p>CarBAMazepine: CYP3A4 Inducers (Strong) may decrease the serum concentration of CarBAMazepine. <i> Monitor therapy</i></p><p>Cariprazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cariprazine. <i> Avoid combination</i></p><p>Cenobamate: May increase the serum concentration of PHENobarbital.<i> Monitor therapy</i></p><p>Ceritinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ceritinib. <i> Avoid combination</i></p><p>Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Monitor therapy</i></p><p>Chloramphenicol (Systemic): May decrease the metabolism of Barbiturates. Barbiturates may increase the metabolism of Chloramphenicol (Systemic).<i> Monitor therapy</i></p><p>Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Consider therapy modification</i></p><p>Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Monitor therapy</i></p><p>ChlorproPAMIDE: CYP3A4 Inducers (Strong) may decrease the serum concentration of ChlorproPAMIDE. <i> Monitor therapy</i></p><p>Cholestyramine Resin: May decrease the serum concentration of PHENobarbital. Management: Administer phenobarbital at least 1 hour before or 4-6 hours after administration of cholestyramine in order to minimize the risk for any significant interaction.<i> Consider therapy modification</i></p><p>Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Avoid combination</i></p><p>Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.  Management: Consider alternative antimicrobial therapy for patients receiving a CYP3A inducer. Drugs that enhance the metabolism of clarithromycin into 14-hydroxyclarithromycin may alter the clinical activity of clarithromycin and may impair clarithromycin efficacy.<i> Consider therapy modification</i></p><p>Clindamycin (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Clindamycin (Systemic). Refer to the specific clindamycin (systemic) - rifampin drug interaction monograph for information concerning that combination. <i> Monitor therapy</i></p><p>CloZAPine: CYP3A4 Inducers (Strong) may decrease the serum concentration of CloZAPine.  Management: Avoid use with strong CYP3A4 inducers when possible. If combined, monitor patients closely and consider clozapine dose increases. Clozapine dose reduction and further monitoring may be required when strong CYP3A4 inducers are discontinued.<i> Consider therapy modification</i></p><p>CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Consider therapy modification</i></p><p>CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Monitor therapy</i></p><p>Cobicistat: PHENobarbital may decrease the serum concentration of Cobicistat. <i> Avoid combination</i></p><p>Cobimetinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cobimetinib. <i> Avoid combination</i></p><p>Codeine: PHENobarbital may enhance the CNS depressant effect of Codeine. PHENobarbital may decrease the serum concentration of Codeine.  Management: Avoid use of codeine and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased codeine efficacy and withdrawal if combined.<i> Consider therapy modification</i></p><p>Copanlisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Copanlisib. <i> Avoid combination</i></p><p>Cosyntropin: May enhance the hepatotoxic effect of PHENobarbital.<i> Monitor therapy</i></p><p>Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib. <i> Avoid combination</i></p><p>CycloSPORINE (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of CycloSPORINE (Systemic).  Management: Monitor closely for reduced cyclosporine concentrations when combined with strong CYP3A4 inducers. Cyclosporine dose increases will likely be required to maintain adequate serum concentrations.<i> Consider therapy modification</i></p><p>CYP3A4 Substrates (High risk with Inducers): CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates (High risk with Inducers).  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Consider therapy modification</i></p><p>Dabigatran Etexilate: PHENobarbital may decrease the serum concentration of Dabigatran Etexilate. <i> Monitor therapy</i></p><p>Dabrafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dabrafenib. <i> Monitor therapy</i></p><p>Daclatasvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Daclatasvir. <i> Avoid combination</i></p><p>Dapsone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Dapsone (Systemic). <i> Monitor therapy</i></p><p>Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Monitor therapy</i></p><p>Darunavir: May decrease the serum concentration of PHENobarbital.<i> Monitor therapy</i></p><p>Dasabuvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasabuvir. <i> Avoid combination</i></p><p>Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.<i> Consider therapy modification</i></p><p>Deferasirox: PHENobarbital may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.<i> Consider therapy modification</i></p><p>Deflazacort: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Deflazacort. <i> Avoid combination</i></p><p>Delamanid: CYP3A4 Inducers (Strong) may decrease the serum concentration of Delamanid. <i> Avoid combination</i></p><p>DexAMETHasone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of DexAMETHasone (Systemic).  Management: Consider dexamethasone dose increases in patients receiving strong CYP3A4 inducers and monitor closely for reduced dexamethasone efficacy. Consider avoiding this combination when treating life threatening conditions (ie, multiple myeloma).<i> Consider therapy modification</i></p><p>Dexmethylphenidate: May increase the serum concentration of PHENobarbital.<i> Monitor therapy</i></p><p>Dienogest: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dienogest. <i> Avoid combination</i></p><p>Diethylstilbestrol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Diethylstilbestrol. <i> Monitor therapy</i></p><p>Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Disopyramide: PHENobarbital may decrease the serum concentration of Disopyramide. <i> Monitor therapy</i></p><p>Disulfiram: May enhance the adverse/toxic effect of Products Containing Ethanol. Management: Do not use disulfiram with dosage forms that contain ethanol.<i> Avoid combination</i></p><p>Dolutegravir: PHENobarbital may decrease the serum concentration of Dolutegravir. <i> Avoid combination</i></p><p>Doravirine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Doravirine. <i> Avoid combination</i></p><p>Doxercalciferol: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Doxercalciferol. <i> Monitor therapy</i></p><p>DOXOrubicin (Conventional): CYP3A4 Inducers (Strong) may decrease the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to strong CYP3A4 inducers in patients treated with doxorubicin whenever possible. Prescribing information for at least one doxorubicin product recommends that these combinations be avoided.<i> Consider therapy modification</i></p><p>Doxycycline: Barbiturates may decrease the serum concentration of Doxycycline. <i> Monitor therapy</i></p><p>Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Monitor therapy</i></p><p>Dronabinol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronabinol. <i> Monitor therapy</i></p><p>Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone. <i> Avoid combination</i></p><p>Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Consider therapy modification</i></p><p>Duvelisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Duvelisib. <i> Avoid combination</i></p><p>Elagolix: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elagolix. <i> Monitor therapy</i></p><p>Elbasvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elbasvir. <i> Avoid combination</i></p><p>Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor. <i> Avoid combination</i></p><p>Eliglustat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eliglustat. <i> Avoid combination</i></p><p>Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Avoid combination</i></p><p>Elvitegravir: PHENobarbital may decrease the serum concentration of Elvitegravir. <i> Avoid combination</i></p><p>Encorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Encorafenib. <i> Avoid combination</i></p><p>Enfortumab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enfortumab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased. <i> Monitor therapy</i></p><p>Entrectinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Entrectinib. <i> Avoid combination</i></p><p>Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.  Management: Consider using an alternative agent that has no or minimal CYP3A4 induction potential when possible.  If this combination cannot be avoided, increase the dose of enzalutamide from 160 mg daily to 240 mg daily.<i> Consider therapy modification</i></p><p>EPHEDrine (Systemic): Atropine (Systemic) may enhance the therapeutic effect of EPHEDrine (Systemic). <i> Monitor therapy</i></p><p>Eravacycline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eravacycline.  Management: Increase the eravacycline dose to 1.5 mg/kg every 12 hours when combined with strong CYP3A4 inducers.<i> Consider therapy modification</i></p><p>Erdafitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Erdafitinib. <i> Avoid combination</i></p><p>Erlotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Erlotinib.  Management: Avoid combination if possible.  If combination must be used, increase erlotinib dose by 50 mg increments every 2 weeks as tolerated, to a maximum of 450 mg/day.<i> Consider therapy modification</i></p><p>Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Eslicarbazepine: PHENobarbital may decrease the serum concentration of Eslicarbazepine. <i> Monitor therapy</i></p><p>Estriol (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Estriol (Systemic). <i> Monitor therapy</i></p><p>Estriol (Topical): CYP3A4 Inducers (Strong) may decrease the serum concentration of Estriol (Topical). <i> Monitor therapy</i></p><p>Estrogen Derivatives (Contraceptive): Barbiturates may diminish the therapeutic effect of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible.  Management: Use of a non-hormonal contraceptive is recommended. Breakthrough bleeding, though an important sign regarding the diminished effect of oral contraceptives, might not be present in spite of the occurrence of an interaction.<i> Consider therapy modification</i></p><p>Etizolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etizolam. <i> Monitor therapy</i></p><p>Etoposide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoposide.  Management: When possible, seek alternatives to strong CYP3A4-inducing medications in patients receiving etoposide. If combined, monitor patients closely for diminished etoposide response and need for etoposide dose increases.<i> Consider therapy modification</i></p><p>Etoposide Phosphate: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoposide Phosphate.  Management: When possible, seek alternatives to strong CYP3A4-inducing medications in patients receiving etoposide phosphate. If these combinations cannot be avoided, monitor patients closely for diminished etoposide phosphate response.<i> Consider therapy modification</i></p><p>Etravirine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etravirine. <i> Avoid combination</i></p><p>Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers if possible. If coadministration cannot be avoided, monitor for decreased everolimus serum concentrations and effects, and adjust everolimus dose as needed.<i> Consider therapy modification</i></p><p>Evogliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Evogliptin. <i> Monitor therapy</i></p><p>Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Increase the exemestane dose to 50 mg/day in patients receiving concurrent strong CYP3A4 inducers. Monitor patients closely for evidence of toxicity or inadequate clinical response.<i> Consider therapy modification</i></p><p>Fedratinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Fedratinib. <i> Avoid combination</i></p><p>Felbamate: PHENobarbital may decrease the serum concentration of Felbamate. Felbamate may increase the serum concentration of PHENobarbital.  Management: In patients receiving phenobarbital, initiate felbamate at 1200 mg/day in divided doses 3-4 times daily and reduce phenobarbital dose by 20%. Monitor for increased phenobarbital concentrations/effects and decreased felbamate concentrations/effects.<i> Consider therapy modification</i></p><p>FentaNYL: PHENobarbital may enhance the CNS depressant effect of FentaNYL. PHENobarbital may decrease the serum concentration of FentaNYL.  Management: Avoid use of fentanyl and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased fentanyl efficacy and withdrawal if combined.<i> Consider therapy modification</i></p><p>Fexinidazole [INT]: May increase the serum concentration of Products Containing Propylene Glycol.<i> Avoid combination</i></p><p>Flibanserin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Flibanserin. <i> Avoid combination</i></p><p>Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Consider therapy modification</i></p><p>Folic Acid: May decrease the serum concentration of PHENobarbital.<i> Monitor therapy</i></p><p>Fosaprepitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Fosaprepitant. Specifically, CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite aprepitant. <i> Avoid combination</i></p><p>Fosnetupitant: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fosnetupitant. <i> Avoid combination</i></p><p>Fosphenytoin: May enhance the CNS depressant effect of PHENobarbital. Fosphenytoin may increase the serum concentration of PHENobarbital. PHENobarbital may decrease the serum concentration of Fosphenytoin.<i> Monitor therapy</i></p><p>Fostamatinib: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fostamatinib. <i> Avoid combination</i></p><p>Fostemsavir: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fostemsavir. <i> Avoid combination</i></p><p>Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Monitor therapy</i></p><p>Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse reactions, increase gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers; resume 250 mg dose 7 days after discontinuation of the strong inducer.  Carefully monitor clinical response.<i> Consider therapy modification</i></p><p>Gemigliptin: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Gemigliptin. CYP3A4 Inducers (Strong) may decrease the serum concentration of Gemigliptin. <i> Avoid combination</i></p><p>Gestrinone: PHENobarbital may decrease the serum concentration of Gestrinone. <i> Monitor therapy</i></p><p>Glasdegib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Glasdegib. <i> Avoid combination</i></p><p>Glecaprevir and Pibrentasvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Glecaprevir and Pibrentasvir. <i> Monitor therapy</i></p><p>Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Monitor therapy</i></p><p>Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Avoid combination</i></p><p>Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>Grazoprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Grazoprevir. <i> Avoid combination</i></p><p>Griseofulvin: Barbiturates may decrease the serum concentration of Griseofulvin. <i> Monitor therapy</i></p><p>GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Increase extended-release guanfacine dose by up to double when initiating guanfacine in patients taking CYP3A4 inducers or if initiating a CYP3A4 inducer in a patient already taking extended-release guanfacine. Monitor for reduced guanfacine efficacy.<i> Consider therapy modification</i></p><p>Hemin: Barbiturates may diminish the therapeutic effect of Hemin. <i> Avoid combination</i></p><p>HYDROcodone: PHENobarbital may enhance the CNS depressant effect of HYDROcodone. PHENobarbital may decrease the serum concentration of HYDROcodone.  Management: Avoid use of hydrocodone and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased hydrocodone efficacy and withdrawal if combined.<i> Consider therapy modification</i></p><p>Hydrocortisone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Hydrocortisone (Systemic). <i> Monitor therapy</i></p><p>HydrOXYzine: May enhance the CNS depressant effect of Barbiturates. Management: Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine.  With concurrent use, monitor patients closely for excessive response to the combination.<i> Consider therapy modification</i></p><p>Ibrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ibrutinib. <i> Avoid combination</i></p><p>Idelalisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Idelalisib. <i> Avoid combination</i></p><p>Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Monitor therapy</i></p><p>Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.<i> Consider therapy modification</i></p><p>Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>Irinotecan Products: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Irinotecan Products. <i> Avoid combination</i></p><p>Isavuconazonium Sulfate: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inducers (Strong) may decrease isavuconazole serum concentrations. <i> Avoid combination</i></p><p>Istradefylline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Istradefylline. <i> Avoid combination</i></p><p>Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Monitor therapy</i></p><p>Itraconazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole. <i> Avoid combination</i></p><p>Ivabradine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivabradine. <i> Avoid combination</i></p><p>Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor. <i> Avoid combination</i></p><p>Ivosidenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivosidenib. <i> Avoid combination</i></p><p>Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m<sup>2</sup> to 60 mg/m<sup>2</sup> (given as a 4-hour infusion), as tolerated, should be considered.<i> Consider therapy modification</i></p><p>Ixazomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixazomib. <i> Avoid combination</i></p><p>Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Monitor therapy</i></p><p>Ketoconazole (Systemic): Hyoscyamine may decrease the serum concentration of Ketoconazole (Systemic).  Management: Take hyoscyamine at least 2 hours after ingestion of ketoconazole. Monitor for decreased therapeutic effects of ketoconazole if used together with hyoscyamine.<i> Consider therapy modification</i></p><p>LamoTRIgine: PHENobarbital may enhance the adverse/toxic effect of LamoTRIgine. Specifically, the risk for hematologic toxicities may be increased. PHENobarbital may decrease the serum concentration of LamoTRIgine.  Management: For patients taking phenobarbital without valproate, lamotrigine dose adjustments are recommended for lamotrigine initiation. Recommendations vary based on lamotrigine indication and age. See full interact monograph for details.<i> Consider therapy modification</i></p><p>Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If concomitant use cannot be avoided, titrate lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.<i> Consider therapy modification</i></p><p>Larotrectinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Larotrectinib.  Management: Avoid use of strong CYP3A4 inducers with larotrectinib. If this combination cannot be avoided, double the larotrectinib dose. Reduced to previous dose after stopping the inducer after a period of 3 to 5 times the inducer's half-life.<i> Consider therapy modification</i></p><p>Ledipasvir: PHENobarbital may decrease the serum concentration of Ledipasvir. <i> Avoid combination</i></p><p>Lefamulin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin with strong CYP3A4 inducers unless the benefits outweigh the risks.<i> Consider therapy modification</i></p><p>Lefamulin (Intravenous): CYP3A4 Inducers (Strong) may decrease the serum concentration of Lefamulin (Intravenous).  Management: Avoid concomitant use of lefamulin intravenous infusion with strong CYP3A4 inducers unless the benefits outweigh the risks.<i> Consider therapy modification</i></p><p>Lemborexant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lemborexant. <i> Avoid combination</i></p><p>Letermovir: May increase the serum concentration of UGT1A1 Inducers.<i> Avoid combination</i></p><p>Leucovorin Calcium-Levoleucovorin: May decrease the serum concentration of PHENobarbital.<i> Monitor therapy</i></p><p>LevETIRAcetam: PHENobarbital may decrease the serum concentration of LevETIRAcetam. <i> Monitor therapy</i></p><p>Levomefolate: May decrease the serum concentration of PHENobarbital.<i> Monitor therapy</i></p><p>Levonorgestrel (IUD): CYP3A4 Inducers (Strong) may diminish the therapeutic effect of Levonorgestrel (IUD). CYP3A4 Inducers (Strong) may decrease the serum concentration of Levonorgestrel (IUD). <i> Monitor therapy</i></p><p>Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Avoid combination</i></p><p>LinaGLIPtin: CYP3A4 Inducers (Strong) may decrease the serum concentration of LinaGLIPtin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.<i> Consider therapy modification</i></p><p>Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Monitor therapy</i></p><p>Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Lopinavir: PHENobarbital may decrease the serum concentration of Lopinavir.  Management: Increased doses of lopinavir may be necessary when using these agents in combination.  Do not use a once daily lopinavir/ritonavir regimen together with phenobarbital. Increase monitoring of therapeutic response in all patients using this combination.<i> Consider therapy modification</i></p><p>Lorlatinib: CYP3A4 Inducers (Strong) may enhance the hepatotoxic effect of Lorlatinib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Lorlatinib. <i> Avoid combination</i></p><p>Lumacaftor and Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lumacaftor and Ivacaftor. Specifically, the serum concentration of ivacaftor may be decreased. <i> Avoid combination</i></p><p>Lumateperone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lumateperone. <i> Avoid combination</i></p><p>Lumefantrine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lumefantrine. <i> Avoid combination</i></p><p>Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone. <i> Avoid combination</i></p><p>Lurbinectedin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurbinectedin. <i> Avoid combination</i></p><p>Macimorelin: Atropine (Systemic) may diminish the diagnostic effect of Macimorelin. <i> Avoid combination</i></p><p>Macitentan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Macitentan. <i> Avoid combination</i></p><p>Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Manidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Manidipine.  Management: Consider avoiding concomitant use of manidipine and strong CYP3A4 inducers. If combined, monitor closely for decreased manidipine effects and loss of efficacy. Increased manidipine doses may be required.<i> Consider therapy modification</i></p><p>Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600mg twice/day, but only in the absence of a concurrent strong CYP3A4 inhibitor. Not recommended for pediatric patients not also receiving a strong CYP3A4 inhibitor. Do not use in patients with CrCl less than 30 mL/min.<i> Consider therapy modification</i></p><p>Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  If anticonvulsants are being used for another indication, monitor anticonvulsant concentrations and treatment response closely with concurrent use.<i> Consider therapy modification</i></p><p>Methotrimeprazine: Products Containing Ethanol may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, CNS depressant effects may be increased.  Management: Avoid products containing alcohol in patients treated with methotrimeprazine.<i> Avoid combination</i></p><p>Methoxyflurane: Barbiturates may enhance the nephrotoxic effect of Methoxyflurane. Barbiturates may increase the metabolism of Methoxyflurane. <i> Avoid combination</i></p><p>Methylfolate: May decrease the serum concentration of PHENobarbital.<i> Monitor therapy</i></p><p>Methylphenidate: May increase the serum concentration of PHENobarbital.<i> Monitor therapy</i></p><p>MethylPREDNISolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose increases in patients receiving strong CYP3A4 inducers and monitor closely for reduced steroid efficacy.<i> Consider therapy modification</i></p><p>Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>MetroNIDAZOLE (Systemic): PHENobarbital may decrease the serum concentration of MetroNIDAZOLE (Systemic). <i> Monitor therapy</i></p><p>MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Monitor therapy</i></p><p>Mianserin: May enhance the CNS depressant effect of Barbiturates. Mianserin may diminish the therapeutic effect of Barbiturates. Barbiturates may decrease the serum concentration of Mianserin.<i> Avoid combination</i></p><p>Midostaurin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Midostaurin. <i> Avoid combination</i></p><p>MiFEPRIStone: CYP3A4 Inducers (Strong) may decrease the serum concentration of MiFEPRIStone. <i> Avoid combination</i></p><p>Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Monitor therapy</i></p><p>Mirodenafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mirodenafil.  Management: Consider avoiding the concomitant use of mirodenafil and strong CYP3A4 inducers. If combined, monitor for decreased mirodenafil effects. Mirodenafil dose increases may be required to achieve desired effects.<i> Consider therapy modification</i></p><p>Mirtazapine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mirtazapine. <i> Monitor therapy</i></p><p>Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Barbiturates.<i> Monitor therapy</i></p><p>Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Naldemedine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Naldemedine. <i> Avoid combination</i></p><p>Nalmefene: PHENobarbital may decrease the serum concentration of Nalmefene. <i> Monitor therapy</i></p><p>Naloxegol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Naloxegol. <i> Avoid combination</i></p><p>Nateglinide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nateglinide. <i> Monitor therapy</i></p><p>Neratinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Neratinib. <i> Avoid combination</i></p><p>Netupitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Netupitant. <i> Avoid combination</i></p><p>NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine. <i> Avoid combination</i></p><p>Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib. <i> Avoid combination</i></p><p>NiMODipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NiMODipine. <i> Avoid combination</i></p><p>Nintedanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nintedanib. <i> Monitor therapy</i></p><p>Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine. <i> Avoid combination</i></p><p>Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Monitor therapy</i></p><p>Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Monitor therapy</i></p><p>OLANZapine: CYP1A2 Inducers (Weak) may decrease the serum concentration of OLANZapine. <i> Monitor therapy</i></p><p>Olaparib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Olaparib. <i> Avoid combination</i></p><p>Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Consider therapy modification</i></p><p>Orlistat: May decrease the serum concentration of Anticonvulsants.<i> Monitor therapy</i></p><p>Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Avoid combination</i></p><p>Osilodrostat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Osilodrostat. <i> Monitor therapy</i></p><p>Osimertinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Osimertinib.  Management: Avoid coadministration of osimertinib and strong CYP3A4 inducers if possible. If coadministration is unavoidable, increase osimertinib to 160 mg daily. Reduce osimertinib to 80 mg daily 3 weeks after discontinuation of the strong CYP3A4 inducer.<i> Consider therapy modification</i></p><p>Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>OXcarbazepine: CYP3A4 Inducers (Strong) may decrease the serum concentration of OXcarbazepine. Specifically, the concentrations of the 10-monohydroxy active metabolite of oxcarbazepine may be decreased. <i> Monitor therapy</i></p><p>Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Avoid combination</i></p><p>Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Consider therapy modification</i></p><p>OxyCODONE: PHENobarbital may enhance the CNS depressant effect of OxyCODONE. PHENobarbital may decrease the serum concentration of OxyCODONE.  Management: Avoid use of oxycodone and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased oxycodone efficacy and withdrawal if combined.<i> Consider therapy modification</i></p><p>Palbociclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Palbociclib. <i> Avoid combination</i></p><p>Panobinostat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Panobinostat. <i> Avoid combination</i></p><p>Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Avoid combination</i></p><p>PAZOPanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of PAZOPanib. <i> Avoid combination</i></p><p>Pemigatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pemigatinib. <i> Avoid combination</i></p><p>Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Increase the perampanel starting dose to 4 mg/day when perampanel is used concurrently with moderate and strong CYP3A4 inducers. Monitor response to perampanel, particularly with changes to CYP3A4 inducer therapy.<i> Consider therapy modification</i></p><p>Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Consider therapy modification</i></p><p>Pexidartinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pexidartinib. <i> Avoid combination</i></p><p>Phenytoin: May enhance the CNS depressant effect of PHENobarbital. PHENobarbital may decrease the serum concentration of Phenytoin. Phenytoin may increase the serum concentration of PHENobarbital.<i> Monitor therapy</i></p><p>Pimavanserin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pimavanserin. <i> Avoid combination</i></p><p>Piperaquine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Piperaquine. <i> Avoid combination</i></p><p>Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Monitor therapy</i></p><p>Pitolisant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pitolisant.  Management: If on a stable pitolisant dose of 8.9 mg or 17.8 mg/day and starting a strong CYP3A4 inducer, double the pitolisant dose over 7 days (ie, to either 17.8 mg/day or 35.6 mg/day, respectively). Reduce pitolisant dose by 50% when the inducer is discontinued.<i> Consider therapy modification</i></p><p>Polatuzumab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Polatuzumab Vedotin. Exposure to unconjugated MMAE, the cytotoxic small molecule component of polatuzumab vedotin, may be decreased. <i> Monitor therapy</i></p><p>PONATinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of PONATinib. <i> Avoid combination</i></p><p>Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Avoid combination</i></p><p>Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Avoid combination</i></p><p>Pralsetinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pralsetinib.  Management: Avoid concomitant use of pralsetinib with strong CYP3A4 inducers when possible. If combined, increase the starting dose of pralsetinib to double the current pralsetinib dosage starting on day 7 of coadministration.<i> Consider therapy modification</i></p><p>Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Monitor therapy</i></p><p>Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Avoid combination</i></p><p>Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Use of praziquantel with strong CYP3A4 inducers is contraindicated. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.<i> Avoid combination</i></p><p>PrednisoLONE (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of PrednisoLONE (Systemic). <i> Monitor therapy</i></p><p>PredniSONE: CYP3A4 Inducers (Strong) may decrease the serum concentration of PredniSONE. <i> Monitor therapy</i></p><p>Pretomanid: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pretomanid. <i> Avoid combination</i></p><p>Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Monitor therapy</i></p><p>Primidone: May enhance the adverse/toxic effect of Barbiturates. Primidone is converted to phenobarbital, and thus becomes additive with existing barbiturate therapy.<i> Monitor therapy</i></p><p>Progestins (Contraceptive): Barbiturates may diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible.  Management: Use of alternative, nonhormonal contraceptives is recommended. When using levonorgestrel as emergency contraception, non-US guidelines suggest doubling the dose of levonorgestrel to 3 mg in women who have used enzyme inducing drugs in the past 4 weeks.<i> Consider therapy modification</i></p><p>Propacetamol: Barbiturates may increase the metabolism of Propacetamol. This may 1) diminish the desired effects of propacetamol; and 2) increase the risk of liver damage. <i> Monitor therapy</i></p><p>Propafenone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Propafenone. <i> Monitor therapy</i></p><p>Pyridoxine: May increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day)<i> Monitor therapy</i></p><p>QUEtiapine: CYP3A4 Inducers (Strong) may decrease the serum concentration of QUEtiapine.  Management: An increase in quetiapine dose (as much as 5 times the regular dose) may be required to maintain therapeutic benefit. Reduce the quetiapine dose back to the previous/regular dose within 7-14 days of discontinuing the inducer.<i> Consider therapy modification</i></p><p>QuiNIDine: PHENobarbital may enhance the hepatotoxic effect of QuiNIDine. PHENobarbital may decrease the serum concentration of QuiNIDine. <i> Monitor therapy</i></p><p>QuiNINE: May increase the serum concentration of PHENobarbital. PHENobarbital may decrease the serum concentration of QuiNINE. Management: Consider avoiding this combination. If coadministration cannot be avoided, monitor for reduced quinine efficacy and for signs/symptoms of phenobarbital toxicity. Monitor phenobarbital serum concentrations as appropriate.<i> Consider therapy modification</i></p><p>Radotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Radotinib.  Management: Consider alternatives to this combination when possible as the risk of radotinib treatment failure may be increased.<i> Consider therapy modification</i></p><p>Ramelteon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ramelteon. <i> Monitor therapy</i></p><p>Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Monitor therapy</i></p><p>Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine. <i> Avoid combination</i></p><p>Reboxetine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Reboxetine. <i> Monitor therapy</i></p><p>Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib. <i> Avoid combination</i></p><p>Remdesivir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Remdesivir. <i> Monitor therapy</i></p><p>Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Avoid combination</i></p><p>Ribociclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ribociclib. <i> Avoid combination</i></p><p>Rifamycin Derivatives: May increase the metabolism of Barbiturates.<i> Monitor therapy</i></p><p>Rilpivirine: PHENobarbital may decrease the serum concentration of Rilpivirine. <i> Avoid combination</i></p><p>Rimegepant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rimegepant. <i> Avoid combination</i></p><p>Ripretinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ripretinib. <i> Avoid combination</i></p><p>RisperiDONE: CYP3A4 Inducers (Strong) may decrease the serum concentration of RisperiDONE.  Management: Consider increasing the dose of oral risperidone (to no more than double the original dose) if a strong CYP3A4 inducer is initiated. For patients on IM risperidone, consider an increased IM dose or supplemental doses of oral risperidone.<i> Consider therapy modification</i></p><p>Ritodrine: Atropine (Systemic) may enhance the adverse/toxic effect of Ritodrine. <i> Monitor therapy</i></p><p>Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban. <i> Monitor therapy</i></p><p>Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.<i> Avoid combination</i></p><p>Rolapitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rolapitant.  Management: Avoid rolapitant use in patients requiring chronic administration of strong CYP3A4 inducers.  Monitor for reduced rolapitant response and the need for alternative or additional antiemetic therapy even with shorter-term use of such inducers.<i> Consider therapy modification</i></p><p>RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin. <i> Avoid combination</i></p><p>ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Monitor therapy</i></p><p>Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Monitor therapy</i></p><p>Rufinamide: May increase the serum concentration of PHENobarbital. PHENobarbital may decrease the serum concentration of Rufinamide.<i> Monitor therapy</i></p><p>Ruxolitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ruxolitinib. <i> Monitor therapy</i></p><p>Sacituzumab Govitecan: UGT1A1 Inducers may decrease serum concentrations of the active metabolite(s) of Sacituzumab Govitecan. Specifically, concentrations of SN-38 may be decreased. <i> Avoid combination</i></p><p>Sapropterin: PHENobarbital may decrease the serum concentration of Sapropterin. Specifically, phenobarbital may decrease tissue concentrations of tetrahydrobiopterin. <i> Monitor therapy</i></p><p>SAXagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of SAXagliptin. <i> Monitor therapy</i></p><p>Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Consider therapy modification</i></p><p>Selpercatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Selpercatinib. <i> Avoid combination</i></p><p>Selumetinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Selumetinib. <i> Avoid combination</i></p><p>Sertraline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sertraline. <i> Monitor therapy</i></p><p>Simeprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Simeprevir. <i> Avoid combination</i></p><p>Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Consider therapy modification</i></p><p>Sirolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sirolimus.  Management: Avoid concomitant use of strong CYP3A4 inducers and sirolimus if possible. If combined, monitor for reduced serum sirolimus concentrations. Sirolimus dose increases will likely be necessary to prevent subtherapeutic sirolimus levels.<i> Consider therapy modification</i></p><p>Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Monitor therapy</i></p><p>Sofosbuvir: PHENobarbital may decrease the serum concentration of Sofosbuvir. <i> Avoid combination</i></p><p>Somatostatin Acetate: May enhance the adverse/toxic effect of Barbiturates. Specifically, Somatostatin Acetate may enhance or prolong Barbiturate effects, including sedative effects.<i> Avoid combination</i></p><p>Sonidegib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sonidegib. <i> Avoid combination</i></p><p>SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib. <i> Avoid combination</i></p><p>Stiripentol: PHENobarbital may decrease the serum concentration of Stiripentol. <i> Avoid combination</i></p><p>SUFentanil: PHENobarbital may enhance the CNS depressant effect of SUFentanil. PHENobarbital may decrease the serum concentration of SUFentanil.  Management: Avoid use of sufentanil and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased sufentanil efficacy and withdrawal if combined.<i> Consider therapy modification</i></p><p>Sulthiame: May enhance the adverse/toxic effect of PHENobarbital.<i> Monitor therapy</i></p><p>SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If combined, increase sunitinib dose to a max of 87.5 mg daily when treating GIST or RCC. Increase sunitinib dose to a max of 62.5 mg daily when treating PNET. Monitor patients for both reduced efficacy and increased toxicities.<i> Consider therapy modification</i></p><p>Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Consider therapy modification</i></p><p>Tacrolimus (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Tacrolimus (Systemic).  Management: Monitor for decreased tacrolimus concentrations and effects when combined with strong CYP3A4 inducers. Tacrolimus dose increases will likely be needed during concomitant use.<i> Consider therapy modification</i></p><p>Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction or BPH: monitor for decreased effectiveness - no standard dose adjustments recommended. Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.<i> Consider therapy modification</i></p><p>Tamoxifen: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. CYP3A4 Inducers (Strong) may decrease the serum concentration of Tamoxifen.  Management: Consider alternatives to concomitant use of strong CYP3A4 inducers and tamoxifen. If the combination cannot be avoided, monitor for reduced therapeutic effects of tamoxifen.<i> Consider therapy modification</i></p><p>Tasimelteon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tasimelteon. <i> Avoid combination</i></p><p>Tazemetostat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tazemetostat. <i> Avoid combination</i></p><p>Telithromycin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Telithromycin. <i> Avoid combination</i></p><p>Temsirolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Temsirolimus.  Management: Avoid concomitant use of temsirolimus and strong CYP3A4 inducers. If coadministration is unavoidable, increase temsirolimus dose to 50 mg per week. Resume previous temsirolimus dose after discontinuation of the strong CYP3A4 inducer.<i> Consider therapy modification</i></p><p>Teniposide: Barbiturates may decrease the serum concentration of Teniposide.  Management: Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.<i> Consider therapy modification</i></p><p>Tenofovir Alafenamide: PHENobarbital may decrease the serum concentration of Tenofovir Alafenamide. <i> Avoid combination</i></p><p>Tetrahydrocannabinol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tetrahydrocannabinol. <i> Monitor therapy</i></p><p>Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Tetrahydrocannabinol and Cannabidiol: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tetrahydrocannabinol and Cannabidiol. <i> Monitor therapy</i></p><p>Tezacaftor and Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tezacaftor and Ivacaftor. <i> Avoid combination</i></p><p>Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Avoid combination</i></p><p>Theophylline Derivatives: Barbiturates may decrease the serum concentration of Theophylline Derivatives. <i> Monitor therapy</i></p><p>Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Monitor therapy</i></p><p>Thiotepa: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inducers (Strong) may decrease the serum concentration of Thiotepa.  Management: Thiotepa prescribing information recommends avoiding concomitant use of thiotepa and strong CYP3A4 inducers. If concomitant use is unavoidable, monitor for adverse effects.<i> Consider therapy modification</i></p><p>Thiothixene: PHENobarbital may decrease the serum concentration of Thiothixene. <i> Monitor therapy</i></p><p>TiaGABine: CYP3A4 Inducers (Strong) may decrease the serum concentration of TiaGABine.  Management: Approximately 2-fold higher tiagabine doses and a more rapid dose titration will likely be required in patients concomitantly taking a strong CYP3A4 inducer.<i> Consider therapy modification</i></p><p>Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor. <i> Avoid combination</i></p><p>Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Avoid combination</i></p><p>Tipranavir: PHENobarbital may decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of PHENobarbital. <i> Monitor therapy</i></p><p>Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib. <i> Avoid combination</i></p><p>Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: Avoid concurrent use of strong CYP3A4 inducers with the Jynarque brand of tolvaptan. For patients receiving the Samsca brand of tolvaptan, monitor patient response to tolvaptan and adjust tolvaptan dose if required.<i> Consider therapy modification</i></p><p>Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Monitor therapy</i></p><p>Toremifene: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Toremifene. CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene. <i> Avoid combination</i></p><p>Trabectedin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Trabectedin. <i> Avoid combination</i></p><p>TraMADol: PHENobarbital may enhance the CNS depressant effect of TraMADol. PHENobarbital may decrease the serum concentration of TraMADol.  Management: Avoid use of tramadol and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased tramadol efficacy and withdrawal if combined.<i> Consider therapy modification</i></p><p>Triamcinolone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Triamcinolone (Systemic). <i> Monitor therapy</i></p><p>Tricyclic Antidepressants: Barbiturates may increase the metabolism of Tricyclic Antidepressants.  Management: Monitor for decreased efficacy of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. Tricyclic antidepressant dose adjustments are likely required.<i> Consider therapy modification</i></p><p>Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Tropisetron: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tropisetron. <i> Monitor therapy</i></p><p>Tucatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tucatinib. <i> Avoid combination</i></p><p>Ubrogepant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ubrogepant. <i> Avoid combination</i></p><p>Udenafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Udenafil. <i> Monitor therapy</i></p><p>Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal. <i> Avoid combination</i></p><p>Ulipristal: Barbiturates may decrease the serum concentration of Ulipristal. <i> Avoid combination</i></p><p>Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>Upadacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Upadacitinib. <i> Avoid combination</i></p><p>Valbenazine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inducers (Strong) may decrease the serum concentration of Valbenazine. <i> Avoid combination</i></p><p>Valproate Products: May increase the serum concentration of Barbiturates. Barbiturates may decrease the serum concentration of Valproate Products.<i> Monitor therapy</i></p><p>Vandetanib: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Vandetanib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib. <i> Avoid combination</i></p><p>Velpatasvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Velpatasvir. <i> Avoid combination</i></p><p>Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.  Management: Avoid coadministration of vemurafenib and strong CYP3A4 inducers if possible. If coadministration is unavoidable, increase the vemurafenib dose by 240 mg as tolerated. Resume prior vemurafenib dose 2 weeks after discontinuation of strong CYP3A4 inducer.<i> Consider therapy modification</i></p><p>Venetoclax: CYP3A4 Inducers (Strong) may decrease the serum concentration of Venetoclax. <i> Avoid combination</i></p><p>Verapamil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Verapamil.  Management: Consider alternatives to this combination. If combined, monitor for reduced verapamil efficacy. Verapamil dose increases may be necessary.<i> Consider therapy modification</i></p><p>Vilazodone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vilazodone.  Management: Consider increasing vilazodone dose by as much as 2-fold (do not exceed 80 mg/day), based on response, in patients receiving strong CYP3A4 inducers for &gt; 14 days. Reduce to the original vilazodone dose over 1 to 2 weeks after inducer discontinuation.<i> Consider therapy modification</i></p><p>VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal). <i> Avoid combination</i></p><p>Vinflunine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vinflunine. <i> Avoid combination</i></p><p>Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists.  Management: Monitor INR more closely. Anticoagulant dose increases of 30% to 60%  may be needed after a barbiturate is initiated or given at an increased dose. Anticoagulant dose decreases may be needed following barbiturate discontinuation or dose reduction.<i> Consider therapy modification</i></p><p>Vorapaxar: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vorapaxar. <i> Avoid combination</i></p><p>Voriconazole: Barbiturates may decrease the serum concentration of Voriconazole. <i> Avoid combination</i></p><p>Vortioxetine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vortioxetine.  Management: Consider increasing the vortioxetine dose to no more than 3 times the original dose when used with a strong drug metabolism inducer for more than 14 days. The vortioxetine dose should be returned to normal within 14 days of stopping the strong inducer.<i> Consider therapy modification</i></p><p>Voxelotor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Voxelotor.  Management: Avoid concomitant use of voxelotor and strong CYP3A4 inducers. If concomitant use is unavoidable, increase the voxelotor dose to 2,500 mg once daily.<i> Consider therapy modification</i></p><p>Voxilaprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Voxilaprevir. <i> Avoid combination</i></p><p>Zaleplon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zaleplon.  Management: Consider the use of an alternative hypnotic that is not metabolized by CYP3A4 in patients receiving strong CYP3A4 inducers. If zaleplon is combined with a strong CYP3A4 inducer, monitor for decreased effectiveness of zaleplon.<i> Consider therapy modification</i></p><p>Zanubrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zanubrutinib. <i> Avoid combination</i></p><p>Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Consider therapy modification</i></p><p>Zonisamide: May enhance the CNS depressant effect of PHENobarbital. PHENobarbital may decrease the serum concentration of Zonisamide.<i> Monitor therapy</i></p><p>Zopiclone: PHENobarbital may enhance the CNS depressant effect of Zopiclone. PHENobarbital may decrease the serum concentration of Zopiclone. <i> Monitor therapy</i></p><p>Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol. <i> Monitor therapy</i></p><h2>Adverse Reactions</h2><p>The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p><p>Frequency not defined. </p><p>Cardiovascular: Palpitations, tachycardia </p><p>Central nervous system: Dizziness, drowsiness, excitement, headache, insomnia, nervousness </p><p>Dermatologic: Hypohidrosis, urticaria </p><p>Gastrointestinal: Ageusia, bloating, constipation, nausea, vomiting, xerostomia </p><p>Genitourinary: Decreased lactation, impotence, urinary hesitancy, urinary retention</p><p>Hypersensitivity: Anaphylaxis, hypersensitivity reaction (may be severe) </p><p>Neuromuscular &amp; skeletal: Musculoskeletal pain, weakness  </p><p>Ophthalmic: Blurred vision, cycloplegia, increased intraocular pressure, mydriasis</p><h2 class="ddc-anchor-offset" id="warnings">Warnings/Precautions</h2><p><b><i>Concerns related to adverse effects:</i></b></p><p>• CNS effects: May cause drowsiness and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p><p>• Diarrhea: May be a sign of incomplete intestinal obstruction; use caution in patients with ileostomy or colostomy.</p><p>• Heat prostration: May occur in the presence of increased environmental temperature; use caution in hot weather and/or exercise.</p><p><b><i>Disease-related concerns:</i></b></p><p>• Cardiovascular disease: Use with caution in patients with coronary artery disease, arrhythmias, tachycardia, heart failure, or hypertension.</p><p>• Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.</p><p>• Gastric ulcer treatment: Use of anticholinergics in gastric ulcer treatment may cause a delay in gastric emptying due to antral stasis.</p><p>• Hepatic impairment: Use with caution in patients with hepatic impairment.</p><p>• Hyperthyroidism: Use with caution in patients with hyperthyroidism.</p><p>• Neuropathy: Use with caution in patients with autonomic neuropathy.</p><p>• Renal impairment: Use with caution in patients with renal impairment.</p><p><b><i>Concurrent drug therapy issues:</i></b></p><p>• Anticoagulants: Use with caution in patients on anticoagulant therapy.</p><p>• Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.</p><p><b><i>Other warnings/precautions:</i></b></p><p>• Appropriate use: Use has not been shown to prevent or treat duodenal ulcers. </p><p>• Withdrawal: Should not be discontinued abruptly because of the possibility of increased seizure frequency (due to phenobarbital component); therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal. </p><h2 class="ddc-anchor-offset" id="pregnancy">Pregnancy Considerations</h2><p>Reproduction studies with this combination have not been done; refer to individual monographs.</p><h2 class="ddc-anchor-offset" id="patient-education">Patient Education</h2><p><b>What is this drug used for?</b></p><p>• It is used to treat irritable bowel syndrome.</p><p>• It is used to treat ulcer disease.</p><p>• It may be given to you for other reasons. Talk with the doctor.</p><p><b>All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:</b></p><p>• Fatigue</p><p>• Anxiety</p><p>• Nausea</p><p>• Vomiting</p><p>• Bloating</p><p>• Constipation</p><p>• Headache</p><p>• Dizziness</p><p>• Loss of strength and energy</p><p>• Dry mouth</p><p>• Change in taste</p><p><b>WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:</b></p><p>• Trouble sleeping</p><p>• Diarrhea</p><p>• Lack of sweat</p><p>• Muscle pain</p><p>• Muscle cramps</p><p>• Fast heartbeat</p><p>• Abnormal heartbeat</p><p>• Difficult urination</p><p>• Vision changes</p><p>• Eye pain</p><p>• Severe eye irritation</p><p>• Sexual dysfunction</p><p>• Stevens-Johnson syndrome/toxic epidermal necrolysis like red, swollen, blistered, or peeling skin (with or without fever); red or irritated eyes; or sores in mouth, throat, nose, or eyes.</p><p>• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.</p><p><b>Note:</b> This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.</p><p><b>Consumer Information Use and Disclaimer:</b> This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.</p><h2>More about atropine / hyoscyamine / phenobarbital / scopolamine</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>49 Reviews</li>
<li>Drug class: anticholinergics/antispasmodics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Belladonna alkaloids and phenobarbital &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Advanced Reading)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li>Phenobarbital with Belladonna Alkaloids Elixir &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
<li>Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate and Scopolamine Hydrobromide Elixir &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
<li>Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate and Scopolamine Hydrobromide Tablets &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Enterocolitis</li>
<li>Duodenal Ulcer</li>
<li>Irritable Bowel Syndrome</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>